Wenyu Fu, Yujianan Chen, Kaidi Wang, Aubryanna Hettinghouse, Wenhuo Hu, Jing-Quan Wang, Zi-Ning Lei, Zhe-Sheng Chen, Kenneth A. Stapleford, Chuan-ju Liu. Repurposing FDA-approved drugs for SARS-CoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interaction[J]. Protein&Cell, 2021, 12(7): 586-591. doi: 10.1007/s13238-020-00803-w
|
Citation:
|
Wenyu Fu, Yujianan Chen, Kaidi Wang, Aubryanna Hettinghouse, Wenhuo Hu, Jing-Quan Wang, Zi-Ning Lei, Zhe-Sheng Chen, Kenneth A. Stapleford, Chuan-ju Liu. Repurposing FDA-approved drugs for SARS-CoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interaction[J]. Protein&Cell, 2021, 12(7): 586-591. doi: 10.1007/s13238-020-00803-w
|
Wenyu Fu, Yujianan Chen, Kaidi Wang, Aubryanna Hettinghouse, Wenhuo Hu, Jing-Quan Wang, Zi-Ning Lei, Zhe-Sheng Chen, Kenneth A. Stapleford, Chuan-ju Liu. Repurposing FDA-approved drugs for SARS-CoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interaction[J]. Protein&Cell, 2021, 12(7): 586-591. doi: 10.1007/s13238-020-00803-w
|
Citation:
|
Wenyu Fu, Yujianan Chen, Kaidi Wang, Aubryanna Hettinghouse, Wenhuo Hu, Jing-Quan Wang, Zi-Ning Lei, Zhe-Sheng Chen, Kenneth A. Stapleford, Chuan-ju Liu. Repurposing FDA-approved drugs for SARS-CoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interaction[J]. Protein&Cell, 2021, 12(7): 586-591. doi: 10.1007/s13238-020-00803-w
|
DownLoad: